search

Kymera Therapeutics Inc (KYMR)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123
Sep 18, 2026

BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123

BofA Securities has raised its price target for Kymera Therapeutics (KYMR) to $144 from $123. The company currently holds an average rating of "buy" and a mean price target of $137.73 among analysts.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish
California State Teachers Retirement System Raises Stock Position in Kymera Therapeutics, Inc. $KYMR
Sep 14, 2026

California State Teachers Retirement System Raises Stock Position in Kymera Therapeutics, Inc. $KYMR

California State Teachers Retirement System significantly increased its holdings in Kymera Therapeutics, Inc. during the second quarter, now owning 7.51% of the company. Despite the company remaining unprofitable, it reported strong revenue growth and beat analyst expectations for its adjusted loss per share. Wall Street analysts maintain a "Moderate Buy" rating for Kymera Therapeutics, although company insiders have sold a substantial amount of stock.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish